Qingmu - China Innovation Driven Pharmaceutical Company

Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Stock code: 688513). Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs. Hit API products such as Bisoprolol and Dabigatran, have been commercialized in regulated markets and China. Qingmu is experienced on exporting API products to more than 40 countries and regions such as Japan, USA, Germany, Spain, the Netherlands, Russia, South Korea, Brazil, etc.

Category: Business > Manufacturing > Pharmaceutical > Drug-manufacturing Upgrade Options